Targeting of makap-pde4d3 complexes in neurodegenerative disease
AssigneeThe United States Government as represented by the Department of Veterans Affairs
InventorsMichael S. Kapiloff, Jeffrey L. Goldberg
Life of this patent
Estimating the term…
Abstract
Nervous system trauma and neurodegeneration including in optic neuropathies are treated by administration of an effective dose of a PDE4D3 displacing agent to promote neurite extension, neuroprotection and recovery. In some embodiments the neurons are optic neurons, including without limitation retinal ganglion cells (RGCs). A cAMP signaling compartment restricted by mAKAPα-anchored PDE4D3 directly regulates neuronal phenotype, and can be molecularly manipulated with therapeutic effect.
Claims29
A method for treating damage to or degenerative diseases of the nervous system, including neurons and glial cells in the brain, spinal cord and visual system including the retina and optic nerves, applied to nervous system cells after trauma, or in neurodegenerative diseases including without limitation glaucoma, traumatic optic neuropathy, ischemic optic neuropathy, retinal or macular degeneration whether age-related or inherited, Alzheimer's disease, stroke, in a mammal, the method comprising:
- administering an effective dose of a PDE4D3 displacing agent to the affected nerve.
Dependencies are inferred from the claim text.